

Timothy D Gilligan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8286442/publications.pdf>

Version: 2024-02-01

133
papers

3,851
citations

172207

29
h-index

143772

57
g-index

136
all docs

136
docs citations

136
times ranked

5474
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline. <i>Journal of Clinical Oncology</i> , 2017, 35, 3618-3632.	0.8	367
2	Testicular cancer. <i>Nature Reviews Disease Primers</i> , 2018, 4, 29.	18.1	299
3	American Society of Clinical Oncology Clinical Practice Guideline on Uses of Serum Tumor Markers in Adult Males With Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2010, 28, 3388-3404.	0.8	246
4	Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62 <i>Clinical Oncology</i> , 2016, 34, 1945-1952.	0.8	202
5	Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1529-1554.	2.3	174
6	Diagnosis and Treatment of Early Stage Testicular Cancer: AUA Guideline. <i>Journal of Urology</i> , 2019, 202, 272-281.	0.2	157
7	Unexpected Association between Induction of Immunity to the Universal Tumor Antigen CYP1B1 and Response to Next Therapy. <i>Clinical Cancer Research</i> , 2005, 11, 4430-4436.	3.2	153
8	Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma. , 2018, 6, 9.		141
9	Chemotherapy for prostate cancer. <i>Urology</i> , 2002, 60, 94-100.	0.5	108
10	African-American men's perceptions about prostate cancer: Implications for designing educational interventions. <i>Social Science and Medicine</i> , 2007, 64, 2189-2200.	1.8	107
11	Racial Differences in Screening for Prostate Cancer in the Elderly. <i>Archives of Internal Medicine</i> , 2004, 164, 1858.	4.3	97
12	A Phase II Study of Pazopanib in Patients with Localized Renal Cell Carcinoma to Optimize Preservation of Renal Parenchyma. <i>Journal of Urology</i> , 2015, 194, 297-303.	0.2	80
13	Ethical decision-making in critical care in Hong Kong. <i>Critical Care Medicine</i> , 1998, 26, 447-451.	0.4	74
14	Social disparities and prostate cancer: mapping the gaps in our knowledge. <i>Cancer Causes and Control</i> , 2005, 16, 45-53.	0.8	73
15	Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2019, 20, 1386-1394.	5.1	69
16	A Church-Based Intervention to Promote Informed Decision Making for Prostate Cancer Screening Among African American Men. <i>Journal of the National Medical Association</i> , 2010, 102, 164-173.	0.6	66
17	Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. <i>Cancer</i> , 2010, 116, 5383-5390.	2.0	63
18	The REDE Model of Healthcare Communication: Optimizing Relationship as a Therapeutic Agent. <i>Journal of Patient Experience</i> , 2014, 1, 8-13.	0.4	60

#	ARTICLE	IF	CITATIONS
19	Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer. <i>Annals of Oncology</i> , 2015, 26, 833-838.	0.6	57
20	Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab. , 2018, 6, 107.		52
21	Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target. <i>Clinical Cancer Research</i> , 2019, 25, 210-221.	3.2	48
22	Obstetric Complications in Pulmonary and Critical Care Medicine. <i>Chest</i> , 1996, 110, 791-809.	0.4	46
23	Clinical Activity of Ipilimumab Plus Nivolumab in Patients With Metastatic Nonâ€“Clear Cell Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 429-435.	0.9	45
24	Withdrawing life support. <i>Critical Care Medicine</i> , 1996, 24, 352-353.	0.4	45
25	Pathological evidence of necrosis in recurrent renal mass following treatment with sunitinib. <i>International Journal of Urology</i> , 2007, 14, 1095-1097.	0.5	43
26	Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 405-412.	0.8	40
27	Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline Summary. <i>Journal of Oncology Practice</i> , 2018, 14, 42-46.	2.5	40
28	The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2018, 119, 160-163.	2.9	39
29	Impact of Neoadjuvant Chemotherapy on Pathologic Response in Patients With Upper Tract Urothelial Carcinoma Undergoing Extirpative Surgery. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e1237-e1242.	0.9	34
30	Neoplasms of the Testis. , 2012, , 837-870.e9.		33
31	Absence of a Correlation of Androgen Receptor Gene CAG Repeat Length and Prostate Cancer Risk in an African-American Population. <i>Clinical Prostate Cancer</i> , 2004, 3, 98-103.	2.1	32
32	Defining the Optimal Treatment for Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer Using Decision Analysis. <i>Journal of Clinical Oncology</i> , 2010, 28, 119-125.	0.8	32
33	Impact of race on survival in men with metastatic hormone-refractory prostate cancer. <i>Urology</i> , 2004, 64, 212-217.	0.5	31
34	Whose Death Is It, Anyway?. <i>Annals of Internal Medicine</i> , 1996, 125, 137.	2.0	28
35	Management of Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer. <i>Urologic Clinics of North America</i> , 2007, 34, 137-148.	0.8	27
36	Rapid Withdrawal of Support. <i>Chest</i> , 1995, 108, 1407-1408.	0.4	26

#	ARTICLE	IF	CITATIONS
37	Serum tumor markers and their utilization in the management of germ-cell tumors in adult males. Expert Review of Anticancer Therapy, 2011, 11, 1-4.	1.1	26
38	Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients With Diminished Renal Function. Clinical Genitourinary Cancer, 2018, 16, e879-e892.	0.9	25
39	Intertubular growth in pure seminomas: associations with poor prognostic parameters. Human Pathology, 2005, 36, 640-645.	1.1	23
40	ASCO Clinical Practice Guideline on Uses of Serum Tumor Markers in Adult Males With Germ Cell Tumors. Journal of Oncology Practice, 2010, 6, 199-202.	2.5	23
41	Management of Localized Seminoma, Stage II: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009. Urology, 2011, 78, S435-S443.	0.5	23
42	Patient Characteristics, Treatment Patterns and Prognostic Factors in Squamous Cell Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, e437-e442.	0.9	23
43	A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy. , 2019, 7, 127.		23
44	Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma. Targeted Oncology, 2018, 13, 599-609.	1.7	22
45	High-Priority Topics for Cancer Quality Measure Development: Results of the 2012 American Society of Clinical Oncology Collaborative Cancer Measure Summit. Journal of Oncology Practice, 2014, 10, e160-e166.	2.5	21
46	Effect of Switching Systemic Treatment After Stereotactic Radiosurgery for Oligoprogressive, Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2018, 16, 413-419.e1.	0.9	21
47	Cessation of vascular endothelial growth factorâ€‘targeted therapy in patients with metastatic renal cell carcinoma. Cancer, 2012, 118, 3277-3282.	2.0	19
48	Clinical Effect of Dose Escalation After Disease Progression in Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2017, 15, e275-e280.	0.9	19
49	End-of-Life Discussions With Patients. Chest, 1996, 109, 11-12.	0.4	17
50	Management of Low-stage Nonseminomatous Germ Cell Tumors of Testis: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009. Urology, 2011, 78, S444-S455.	0.5	17
51	Quality of life among testis cancer survivors. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 413-419.	0.8	17
52	Prognostic Factors and Risk Stratification in Invasive Upper Tract Urothelial Carcinoma. Clinical Genitourinary Cancer, 2018, 16, e751-e760.	0.9	17
53	The Atypical Urothelial Cancer Patient: Management of Bladder Cancers of Nonâ€‘Transitional Cell Histology and Cancers of the Ureters and Renal Pelvis. Seminars in Oncology, 2007, 34, 145-153.	0.8	16
54	Testicular Cancer Survivorship. Hematology/Oncology Clinics of North America, 2011, 25, 627-639.	0.9	15

#	ARTICLE	IF	CITATIONS
55	Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies. <i>Targeted Oncology</i> , 2018, 13, 353-361.	1.7	14
56	Blood Myeloid-Derived Suppressor Cells Correlate with Neutrophil-to-Lymphocyte Ratio and Overall Survival in Metastatic Urothelial Carcinoma. <i>Targeted Oncology</i> , 2020, 15, 211-220.	1.7	14
57	Rates of Biochemical Remission Remain Higher in Black Men Compared to White Men After Radical Prostatectomy Despite Similar Trends in Prostate Specific Antigen Induced Stage Migration. <i>Journal of Urology</i> , 2007, 178, 1271-1276.	0.2	12
58	The ASCO Quality Training Program: Designing and Implementing a Medical Specialty Society-Based Quality Improvement Training Program. <i>Journal of Oncology Practice</i> , 2014, 10, 203-205.	2.5	12
59	Drug Holiday in Metastatic Renal-Cell Carcinoma Patients Treated With Vascular Endothelial Growth Factor Receptor Inhibitors. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e663-e667.	0.9	12
60	Patient-Clinician Communication Is a Joint Creation: Working Together Toward Well-Being. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 532-539.	1.8	11
61	Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy. <i>Prostate</i> , 2018, 78, 1035-1041.	1.2	11
62	Myeloid-Derived Suppressor Cells in Nonmetastatic Urothelial Carcinoma of Bladder Is Associated With Pathologic Complete Response and Overall Survival. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 500-508.	0.9	10
63	Nivolumab treatment for patients with non-clear cell renal cell carcinoma: A multicenter retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4586-4586.	0.8	10
64	Bicalutamide Monotherapy Compared with Castration in Patients with Nonmetastatic Locally Advanced Prostate Cancer: 6.3 Years of Follow-up. <i>Prostate Journal</i> , 2001, 3, 42-43.	0.2	9
65	Management of poor-prognosis testicular germ cell tumors. <i>Indian Journal of Urology</i> , 2010, 26, 108.	0.2	9
66	Immunological correlates of response to immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2018, 36, 454-454.	0.8	9
67	Challenges With the 8th Edition of the AJCC Cancer Staging Manual for Breast, Testicular, and Head and Neck Cancers. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 560-564.	2.3	8
68	Decision Making in a Data-Poor Environment: Management of Brain Metastases From Testicular and Extragenital Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2016, 34, 303-306.	0.8	7
69	Implications of the United States Preventive Services Task Force Recommendations on Prostate Cancer Stage Migration. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e12-e16.	0.9	6
70	Clinical outcome of patients (Pts) with metastatic renal cell carcinoma (mRCC) progressing on front-line immune-oncology based combination (IO-COMBO) regimens.. <i>Journal of Clinical Oncology</i> , 2018, 36, 613-613.	0.8	6
71	ASCO Quality Training Program: A Five-Year Review. <i>JCO Oncology Practice</i> , 2020, 16, e1243-e1248.	1.4	6
72	Carboplatin for Stage I Seminoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 2971-2972.	0.8	5

#	ARTICLE	IF	CITATIONS
73	Is There Such a Thing as a Cancer Treatment That Isn't Worth Its Cost?. <i>Oncologist</i> , 2012, 17, 3-4.	1.9	5
74	Outcomes of treatment cessation in select metastatic renal cell carcinoma (mRCC) patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4521-4521.	0.8	5
75	Testis cancer: rare, but curable with prompt referral.. <i>Cleveland Clinic Journal of Medicine</i> , 2007, 74, 817-825.	0.6	5
76	The new data on prostate cancer screening: What should we do now?. <i>Cleveland Clinic Journal of Medicine</i> , 2009, 76, 446-448.	0.6	5
77	The Morbidity and Mortality Conference (MMC) in Oncology: A patient safety and root cause analysis (RCA)-driven approach at the Cleveland Clinic Taussig Cancer Institute (TCI).. <i>Journal of Clinical Oncology</i> , 2014, 32, 191-191.	0.8	5
78	Evaluation of T cell infiltration in matched biopsy and nephrectomy samples in renal cell carcinoma. <i>Medicine (United States)</i> , 2018, 97, e12344.	0.4	4
79	The association between facility case volume and overall survival in patients with metastatic renal cell carcinoma in the targeted therapy era. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 470.e19-470.e29.	0.8	4
80	Identifying Prostate Surface Antigen Patterns of Change in Patients with Metastatic Hormone Sensitive Prostate Cancer Treated with Abiraterone and Prednisone. <i>Targeted Oncology</i> , 2020, 15, 477-483.	1.7	4
81	Clinicopathologic factors, treatment patterns, and outcomes in micropapillary urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 439-439.	0.8	4
82	Prostate cancer: To screen or not to screen? The question is complicated. <i>Cleveland Clinic Journal of Medicine</i> , 2021, 88, 17-18.	0.6	4
83	Controversies in the management of early-stage germ cell tumors. <i>Current Oncology Reports</i> , 2009, 11, 235-243.	1.8	3
84	ReCAP: Feasibility and Effectiveness of a Pilot Program to Facilitate Quality Improvement Learning in Oncology: Experience of the American Society of Clinical Oncology Quality Training Program. <i>Journal of Oncology Practice</i> , 2016, 12, 177-177.	2.5	3
85	A 45-Year-Old With Neuroendocrine Carcinoma of the Prostate. <i>Urology</i> , 2013, 81, 714-716.	0.5	2
86	Health and quality of life among survivors of testis cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 390-391.	0.8	2
87	Talking About Death. <i>Journal of Oncology Practice</i> , 2017, 13, 672-674.	2.5	2
88	High-dose chemotherapy and autologous transplantation for testicular germ cell tumors. <i>Advances in Cell and Gene Therapy</i> , 2019, 2, e47.	0.6	2
89	Chemotherapy and Fertility. <i>Current Clinical Urology</i> , 2016, , 97-107.	0.0	2
90	Clinical activity of abiraterone acetate in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 99-99.	0.8	2

#	ARTICLE	IF	CITATIONS
91	Series Introduction. Cleveland Clinic Journal of Medicine, 2011, 78, 24-24.	0.6	2
92	Outcomes and patterns of disease progression in metastatic renal cell carcinoma patients treated with nivolumab.. Journal of Clinical Oncology, 2018, 36, 654-654.	0.8	2
93	When Do We Stop Talking About Curative Care?. Journal of Palliative Medicine, 2003, 6, 657-660.	0.6	1
94	Are we scanning testis cancer patients too often?. Cancer, 2011, 117, 4108-4111.	2.0	1
95	If I Paint a Rosy Picture, Will You Promise Not to Cry?. Journal of Clinical Oncology, 2012, 30, 3421-3423.	0.8	1
96	A Pathologic Fascination With Humanity. Journal of Clinical Oncology, 2018, 36, 425-426.	0.8	1
97	Ethical Issues in the Cardiac Intensive Care Unit. , 2019, , 11-26.e3.		1
98	Ethical Issues of Care in the Cardiac Intensive Care Unit. , 2010, , 9-24.		1
99	Discrepancy between reported progressive disease per radiology report and treating oncologist tumor measurements in patients with metastatic renal cell carcinoma (mRCC) receiving sunitinib.. Journal of Clinical Oncology, 2012, 30, 420-420.	0.8	1
100	Real-world experience with atezolizumab (atezo) in advanced urothelial cancer (UC).. Journal of Clinical Oncology, 2017, 35, e16031-e16031.	0.8	1
101	Adjuvant Chemotherapy in Bladder Cancer: A Good Concept But Whereâ€™s the Proof?. , 2009, , 239-245.		1
102	Implementing a comprehensive physician-communication-skills improvement initiative: The Cleveland Clinic experience.. Journal of Clinical Oncology, 2013, 31, 186-186.	0.8	1
103	Treatment patterns for metastatic hormone-sensitive prostate cancer (mHSPC) progressing after up-front docetaxel in combination with androgen deprivation therapy (D-ADT).. Journal of Clinical Oncology, 2018, 36, 305-305.	0.8	1
104	Overall Survival after Prostate-Specific-Antigen-Detected Recurrence Following Conformal Radiation Therapy.. Prostate Journal, 2001, 3, 43-44.	0.2	0
105	Prospective Trial of the Herbal Supplement PC-SPEC in Patients with Progressive Prostate Cancer.. Prostate Journal, 2001, 3, 44-45.	0.2	0
106	Biochemical Outcome Following External Beam Radiation Therapy With or Without Androgen Suppression Therapy for Clinically Localized Prostate Cancer.. Prostate Journal, 2001, 3, 45-46.	0.2	0
107	Changing Management of Clinical Low-Stage Testicular Cancer. Scientific World Journal, The, 2005, 5, 852-867.	0.8	0
108	Retroperitoneal lymph node dissection versus chemotherapy for stage I testicular nonseminomas. Annals of Oncology, 2005, 16, 172-173.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Republication of SEMPET trial data?. European Journal of Radiology, 2006, 58, 317.	1.2	0
110	DECISION ANALYSIS MODEL FOR CLINICAL STAGE I NON- SEMINOMATOUS GERM CELL TESTICULAR CANCER. Journal of Urology, 2008, 179, 174-174.	0.2	0
111	A case of spermatic cord teratoma in low-stage testicular cancer managed by surveillance. Nature Reviews Urology, 2008, 5, 220-223.	1.4	0
112	Preface. Hematology/Oncology Clinics of North America, 2011, 25, xiii-xiv.	0.9	0
113	667 TECHNICAL FACTORS CAN IMPACT NODE COUNTS FROM RETROPERITONEAL LYMPH NODE DISSECTION FOR TESTIS CANCER. Journal of Urology, 2012, 187, .	0.2	0
114	In Reply. Oncologist, 2013, 18, e2-e2.	1.9	0
115	MP10-06 LOWER-THAN-EXPECT RELAPSE RATE AMONG CONTEMPORARY PATIENTS WITH CLINICAL STAGE I SEMINOMA MANAGED ON SURVEILLANCE. Journal of Urology, 2014, 191, .	0.2	0
116	What We Really Talk About When We Talk About Food. Journal of Clinical Oncology, 2015, 33, 665-666.	0.8	0
117	Chemotherapy Is the Preferred Treatment for Seminomas Relapsing After First-line Chemotherapy. International Journal of Radiation Oncology Biology Physics, 2017, 99, 511.	0.4	0
118	Personalizing Medicine. Journal of Clinical Oncology, 2019, 37, 165-166.	0.8	0
119	Immune cell repertoire in patients with indolent metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2013, 31, 429-429.	0.8	0
120	Withdrawal of Life Support. Critical Care Medicine, 1996, 24, 1608.	0.4	0
121	A phase II study of pazopanib (P) in patients (Pts) with localized renal cell carcinoma (RCC) to enable partial nephrectomy (PN).. Journal of Clinical Oncology, 2014, 32, 4522-4522.	0.8	0
122	Clinical Implications of the Different Histologic Subtypes of Testicular Tumors. , 2015, , 483-489.		0
123	Clinical effect of TKI dose-escalation after disease progression in patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2015, 33, 4562-4562.	0.8	0
124	T cell infiltration (TCI) in matched renal biopsy (bx) and nephrectomy (nx) samples in renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2017, 35, 4587-4587.	0.8	0
125	Atezolizumab (atezo) and subsequent therapies in patients (Pts) with metastatic urothelial carcinoma (mUC) outside clinical trials.. Journal of Clinical Oncology, 2018, 36, 432-432.	0.8	0
126	Impact of neoadjuvant chemotherapy on pathologic outcomes in patients with upper tract urothelial carcinoma undergoing extirpative surgery.. Journal of Clinical Oncology, 2018, 36, 457-457.	0.8	0

#	ARTICLE	IF	CITATIONS
127	The association between HSD3B1 genotype and steroid metabolism in normal and prostate cancer (PCa) tissue.. Journal of Clinical Oncology, 2018, 36, TPS155-TPS155.	0.8	0
128	Response to platinum-based therapy (PBT) and immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC) patients (pts) with genomic alterations (GA) in homologous recombination repair (HRR) genes.. Journal of Clinical Oncology, 2018, 36, 447-447.	0.8	0
129	Cisplatin-based neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC) in patients (pts) with impaired renal function.. Journal of Clinical Oncology, 2018, 36, 446-446.	0.8	0
130	The impact of switching systemic treatment after radiosurgery (SBRT) for oligo-progressive, metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2018, 36, 599-599.	0.8	0
131	Serial changes in PD1/PDL1 expression in metastatic urothelial carcinoma (mUC) patients (pts) treated with immune checkpoint blockade (CPB).. Journal of Clinical Oncology, 2018, 36, 109-109.	0.8	0
132	Implications of the United States Preventive Services Task Force (USPSTF) recommendations on prostate cancer (PCa) stage migration.. Journal of Clinical Oncology, 2019, 37, 5071-5071.	0.8	0
133	Testis Cancer. , 2006, , 851-880.		0